Synta Melanoma Data Coming in May

Luke Timmerman2/2/09

Synta, the Lexington, MA-based developer of cancer drugs, said today it has completed enrolling 630 patients in a clinical trial of its lead product candidate for melanoma that has spread through the body. The company (NASDAQ: SNTA) has a goal of releasing results from the study in May. We profiled Synta’s efforts to develop this drug, elesclomol, last month.

Luke Timmerman is the National Biotech Editor of Xconomy. E-mail him at ltimmerman@xconomy.com Follow @